Does the media refer more to IXHL or LFCR?

In the previous week, Lifecore Biomedical had 21 more articles in the media than Incannex Healthcare. MarketBeat recorded 24 mentions for Lifecore Biomedical and 3 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.08 beat Lifecore Biomedical's score of -0.03 indicating that Incannex Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lifecore Biomedical 3 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IXHL or SLGL?

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Incannex Healthcare. MarketBeat recorded 6 mentions for Sol-Gel Technologies and 3 mentions for Incannex Healthcare. Sol-Gel Technologies' average media sentiment score of 0.81 beat Incannex Healthcare's score of 0.08 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sol-Gel Technologies 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IXHL or MNOV?

In the previous week, MediciNova had 6 more articles in the media than Incannex Healthcare. MarketBeat recorded 9 mentions for MediciNova and 3 mentions for Incannex Healthcare. MediciNova's average media sentiment score of 0.19 beat Incannex Healthcare's score of 0.08 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IXHL or MENS?

Incannex Healthcare presently has a consensus price target of $18.00, indicating a potential upside of 460.75%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, research analysts plainly believe Incannex Healthcare is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, IXHL or MENS?

Jyong Biotech has lower revenue, but higher earnings than Incannex Healthcare. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incannex Healthcare $90K 447.62 -$19.30M -$1.69 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is IXHL or MENS more profitable?

Jyong Biotech's return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -25.62% -24.46% Jyong Biotech N/A N/A N/A

Do analysts rate IXHL or SBTX?

Incannex Healthcare presently has a consensus price target of $18.00, indicating a potential upside of 460.75%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, research analysts plainly believe Incannex Healthcare is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is IXHL or SBTX more profitable?

Incannex Healthcare's return on equity of -25.62% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -25.62% -24.46% Silverback Therapeutics N/A -29.62% -28.20%

Does the media prefer IXHL or SBTX?

In the previous week, Incannex Healthcare had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Incannex Healthcare and 1 mentions for Silverback Therapeutics. Incannex Healthcare's average media sentiment score of 0.08 beat Silverback Therapeutics' score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Silverback Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Incannex Healthcare (IXHL) Competitors

$3.21 -0.04 (-1.23%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.22 +0.01 (+0.34%)

As of 10/2/2026 07:58 PM Eastern

Compare

IXHL vs. LFCR, SLGL, MNOV, MENS, and SBTX

Should you buy Incannex Healthcare stock or one of its competitors? Incannex Healthcare's main competitors and comparable companies include Lifecore Biomedical (LFCR), Sol-Gel Technologies (SLGL), MediciNova (MNOV), Jyong Biotech (MENS), and Silverback Therapeutics (SBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Incannex Healthcare compare to Lifecore Biomedical?

Incannex Healthcare (NASDAQ:IXHL) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Incannex Healthcare currently has a consensus target price of $18.00, indicating a potential upside of 460.75%. Lifecore Biomedical has a consensus target price of $6.50, indicating a potential downside of 0.61%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, research analysts clearly believe Incannex Healthcare is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lifecore Biomedical	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Incannex Healthcare has a beta of 6.97, meaning that its stock price is 597% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

In the previous week, Lifecore Biomedical had 21 more articles in the media than Incannex Healthcare. MarketBeat recorded 24 mentions for Lifecore Biomedical and 3 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.08 beat Lifecore Biomedical's score of -0.03 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifecore Biomedical	3 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Incannex Healthcare has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-25.62%	-24.46%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Incannex Healthcare has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	447.62	-$19.30M	-$1.69	N/A
Lifecore Biomedical	$128.87M	1.92	-$40.50M	-$1.07	N/A

Summary

Incannex Healthcare beats Lifecore Biomedical on 9 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to Sol-Gel Technologies?

Incannex Healthcare (NASDAQ:IXHL) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Incannex Healthcare currently has a consensus target price of $18.00, suggesting a potential upside of 460.75%. Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 174.31%. Given Incannex Healthcare's higher possible upside, analysts clearly believe Incannex Healthcare is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Incannex Healthcare has a beta of 6.97, meaning that its stock price is 597% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Incannex Healthcare. MarketBeat recorded 6 mentions for Sol-Gel Technologies and 3 mentions for Incannex Healthcare. Sol-Gel Technologies' average media sentiment score of 0.81 beat Incannex Healthcare's score of 0.08 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sol-Gel Technologies	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incannex Healthcare has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Incannex Healthcare's return on equity of -25.62% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-25.62%	-24.46%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

Sol-Gel Technologies has higher revenue and earnings than Incannex Healthcare. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	447.62	-$19.30M	-$1.69	N/A
Sol-Gel Technologies	$19.39M	10.43	-$6.13M	-$5.64	N/A

Summary

Sol-Gel Technologies beats Incannex Healthcare on 9 of the 17 factors compared between the two stocks.

How does Incannex Healthcare compare to MediciNova?

Incannex Healthcare (NASDAQ:IXHL) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Incannex Healthcare has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. Incannex Healthcare's return on equity of -25.62% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-25.62%	-24.46%
MediciNova	-1,168.70%	-26.51%	-24.39%

Incannex Healthcare presently has a consensus target price of $18.00, indicating a potential upside of 460.75%. MediciNova has a consensus target price of $7.75, indicating a potential upside of 335.39%. Given Incannex Healthcare's higher possible upside, research analysts clearly believe Incannex Healthcare is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, MediciNova had 6 more articles in the media than Incannex Healthcare. MarketBeat recorded 9 mentions for MediciNova and 3 mentions for Incannex Healthcare. MediciNova's average media sentiment score of 0.19 beat Incannex Healthcare's score of 0.08 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediciNova	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Incannex Healthcare has a beta of 6.97, suggesting that its stock price is 597% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

MediciNova has higher revenue and earnings than Incannex Healthcare. MediciNova is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	447.62	-$19.30M	-$1.69	N/A
MediciNova	$410K	213.69	-$12M	-$0.21	N/A

Summary

MediciNova beats Incannex Healthcare on 11 of the 17 factors compared between the two stocks.

How does Incannex Healthcare compare to Jyong Biotech?

Incannex Healthcare (NASDAQ:IXHL) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Jyong Biotech has lower revenue, but higher earnings than Incannex Healthcare.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	447.62	-$19.30M	-$1.69	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Jyong Biotech's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-25.62%	-24.46%
Jyong Biotech	N/A	N/A	N/A

Incannex Healthcare presently has a consensus price target of $18.00, indicating a potential upside of 460.75%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, research analysts plainly believe Incannex Healthcare is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.4% of Incannex Healthcare shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Incannex Healthcare has a beta of 6.97, suggesting that its stock price is 597% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market.

In the previous week, Incannex Healthcare had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for Incannex Healthcare and 0 mentions for Jyong Biotech. Incannex Healthcare's average media sentiment score of 0.08 beat Jyong Biotech's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Jyong Biotech	Neutral

Summary

Incannex Healthcare beats Jyong Biotech on 9 of the 12 factors compared between the two stocks.

How does Incannex Healthcare compare to Silverback Therapeutics?

Incannex Healthcare (NASDAQ:IXHL) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Incannex Healthcare has a beta of 6.97, indicating that its stock price is 597% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

In the previous week, Incannex Healthcare had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Incannex Healthcare and 1 mentions for Silverback Therapeutics. Incannex Healthcare's average media sentiment score of 0.08 beat Silverback Therapeutics' score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silverback Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Incannex Healthcare presently has a consensus price target of $18.00, indicating a potential upside of 460.75%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, research analysts plainly believe Incannex Healthcare is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Incannex Healthcare's return on equity of -25.62% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-25.62%	-24.46%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Incannex Healthcare has higher revenue and earnings than Silverback Therapeutics. Incannex Healthcare is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	447.62	-$19.30M	-$1.69	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Summary

Incannex Healthcare beats Silverback Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Incannex Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXHL vs. The Competition

Export

Metric	Incannex Healthcare	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$40.27M	$12.27B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	-1.90	802.26	274.71	26.04
Price / Sales	447.62	940.01	656.46	105.16
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	1.55	10.52	10.93	6.31
Net Income	-$19.30M	$2.86B	$3.51B	$362.16M
7 Day Performance	-3.31%	-1.58%	-2.00%	-1.66%
1 Month Performance	-0.93%	-5.55%	-6.19%	-4.68%
1 Year Performance	-77.79%	-2.19%	8.03%	1.57%

Incannex Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXHL Incannex Healthcare	1.2631 of 5 stars	$3.21 -1.2%	$18.00 +460.7%	-77.8%	$40.27M	$90K	N/A	12	News Coverage Earnings Report Analyst Downgrade Gap Up
LFCR Lifecore Biomedical	0.583 of 5 stars	$4.48 +0.4%	$6.50 +45.1%	-6.3%	$168.82M	$128.87M	N/A	382	Analyst Downgrade
SLGL Sol-Gel Technologies	3.2523 of 5 stars	$59.28 -1.2%	$197.50 +233.2%	+106.9%	$168.59M	$19.39M	N/A	28	News Coverage Short Interest Increase
MNOV MediciNova	2.7178 of 5 stars	$3.30 -0.6%	$7.75 +134.8%	+39.1%	$163.41M	$410K	N/A	6	Analyst Forecast Insider Trade Gap Up
MENS Jyong Biotech	N/A	$2.15 +4.4%	N/A	-95.5%	$156.62M	N/A	N/A	27	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IXHL) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incannex Healthcare (IXHL) Competitors

IXHL vs. LFCR, SLGL, MNOV, MENS, and SBTX

How does Incannex Healthcare compare to Lifecore Biomedical?

Summary

How does Incannex Healthcare compare to Sol-Gel Technologies?

Summary

How does Incannex Healthcare compare to MediciNova?

Summary

How does Incannex Healthcare compare to Jyong Biotech?

Summary

How does Incannex Healthcare compare to Silverback Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incannex Healthcare (IXHL) Competitors

IXHL vs. LFCR, SLGL, MNOV, MENS, and SBTX

How does Incannex Healthcare compare to Lifecore Biomedical?

Do analysts recommend IXHL or LFCR?

Do insiders and institutionals believe in IXHL or LFCR?

Which has more volatility & risk, IXHL or LFCR?

Does the media refer more to IXHL or LFCR?

Is IXHL or LFCR more profitable?

Which has higher earnings and valuation, IXHL or LFCR?

Summary

How does Incannex Healthcare compare to Sol-Gel Technologies?

Do analysts recommend IXHL or SLGL?

Which has more volatility and risk, IXHL or SLGL?

Do insiders and institutionals hold more shares of IXHL or SLGL?

Does the media favor IXHL or SLGL?

Is IXHL or SLGL more profitable?

Which has better earnings & valuation, IXHL or SLGL?

Summary

How does Incannex Healthcare compare to MediciNova?

Is IXHL or MNOV more profitable?

Do analysts prefer IXHL or MNOV?

Does the media favor IXHL or MNOV?

Do institutionals & insiders believe in IXHL or MNOV?

Which has more risk and volatility, IXHL or MNOV?

Which has better earnings & valuation, IXHL or MNOV?

Summary

How does Incannex Healthcare compare to Jyong Biotech?

Which has stronger earnings & valuation, IXHL or MENS?

Is IXHL or MENS more profitable?

Do analysts rate IXHL or MENS?

Do insiders & institutionals believe in IXHL or MENS?

Which has more risk and volatility, IXHL or MENS?

Does the media favor IXHL or MENS?

Summary

How does Incannex Healthcare compare to Silverback Therapeutics?

Which has more volatility and risk, IXHL or SBTX?

Does the media prefer IXHL or SBTX?

Do analysts rate IXHL or SBTX?

Do insiders & institutionals believe in IXHL or SBTX?

Is IXHL or SBTX more profitable?

Which has higher valuation and earnings, IXHL or SBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools